Skip to content
Company Analysis

Astrazeneca PLC AZN

A comprehensive view of key metrics, scores, and financial health for Astrazeneca PLC

Overview of AstraZeneca PLC

AZN NYQ
Healthcare Drug Manufacturers - General Mega Cap
AstraZeneca PLC (AZN), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $189.90, about 54.4% overvalued vs fair value, +22.5% 1Y return, placing in the top 25% of its sector.
$189.90
-1.35%
As of March 13, 2026
Previous close • Vol 90d: 33.3%
52-Week Range
Market Cap
$294.40B
Enterprise Value
$318.31B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Astrazeneca PLC.

Top Beats

Quick Facts

Website https://www.astrazeneca.com
HQ Cambridge
Employees 96,100
Fiscal year Dec 31

Next Events

Dividend Mar 23
Earnings Apr 29

Fair Value Snapshot

Bear Base Bull
$79
$87
$94
Current: $189.90 -54% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$58.7B
8.6%%
Gross Profit
$48.1B
9.7%%
R&D Expense
$14.2B
4.8%%
Operating Income (EBIT)
$14.1B
35.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
103.4%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.7B
65.6% of FCF

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Astrazeneca PLC's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
55
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
52
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing AZN's balance between Growth (41.9%), Profitability (31.3%), and Safety (26.9%). Growth 42% Safety 27% Profitability 31%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

74th percentile vs peers
75
Key Signals
Rev Growth YoY 8.6% 73p Revenue CAGR 3Y 9.8% 73p EPS CAGR 3Y 45.9% 93p EPS Growth YoY 45.4% 68p TSR 37.4% 66p
Strengths
  • Eps Cagr 3Y in top 20% of peers (45.9%, 93th percentile)
  • Growth above peer median with strong metric coverage (100%)
  • Gross Profit Margin in top 20% of peers (81.9%, 84th percentile)
Risks

No significant risks identified for this axis.

Profitability

55th percentile vs peers
56
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
48
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Astrazeneca PLC.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$86.53
- - -
-54.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info